118 related articles for article (PubMed ID: 10679994)
1. DNA flow cytometry of non-Hodgkin's lymphomas: correlation with cytologic grade and clinical relapse.
Saikia UN; Dey P; Vohra H; Gupta SK
Diagn Cytopathol; 2000 Mar; 22(3):152-6. PubMed ID: 10679994
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
[TBL] [Abstract][Full Text] [Related]
3. The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
Shpilberg O; Shiff J; Chetrit A; Ramot B; Ben-Bassat I
Cancer; 1994 Dec; 74(11):3029-33. PubMed ID: 7525042
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and grading of non-Hodgkin's lymphomas on fine needle aspiration cytology.
Mathur S; Dawar R; Verma K
Indian J Pathol Microbiol; 2007 Jan; 50(1):46-50. PubMed ID: 17474258
[TBL] [Abstract][Full Text] [Related]
5. Biological heterogeneity of diffuse mixed small and large cell non-Hodgkin's lymphomas assessed by DNA flow cytometry and Ki67.
Palestro G; Pich A; Chiusa L; Geuna M; Ponti R; Kerim S; Novero D; Valente G
Leuk Lymphoma; 1995 Nov; 19(5-6):467-72. PubMed ID: 8590848
[TBL] [Abstract][Full Text] [Related]
6. DNA ploidy, proliferative activities, and immunophenotype of malignant lymphoma: application of flow cytometry.
Horii A; Yoshida J; Hattori K; Honjo Y; Mitani K; Takashima S; Sakai M; Okamoto S; Kubo T
Head Neck; 1998 Aug; 20(5):392-8. PubMed ID: 9663666
[TBL] [Abstract][Full Text] [Related]
7. Results of treating stage III and IV malignant non-Hodgkin's lymphomas (NHL).
Jahn H; Ruffert K; Syrbe G; Kühn R; Jorke D
Arch Geschwulstforsch; 1988; 58(2):113-20. PubMed ID: 2454087
[TBL] [Abstract][Full Text] [Related]
8. Primary extranodal non Hodgkin's lymphoma of the head and neck in adults: a clinicopathological comparison between tonsillar and non tonsillar lymphomas. (Hellenic co-Operative Oncology Group).
Economopoulos T; Fountzilas G; Kostourou A; Daniilidis J; Pavlidis N; Andreopoulou H; Nicolaou A; Papageorgiou E; Mellou S; Dervenoulas J; Stathakis N
Anticancer Res; 1998; 18(6B):4655-60. PubMed ID: 9891536
[TBL] [Abstract][Full Text] [Related]
9. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
Joensuu H; Ristamäki R; Söderström KO; Jalkanen S
J Clin Oncol; 1994 Oct; 12(10):2167-75. PubMed ID: 7931487
[TBL] [Abstract][Full Text] [Related]
10. DNA content in high and intermediate grade non-Hodgkin's lymphoma-prognostic significance and clinicopathological correlations.
Cowan RA; Harris M; Jones M; Crowther D
Br J Cancer; 1989 Dec; 60(6):904-10. PubMed ID: 2605100
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
Conlan MG; Bast M; Armitage JO; Weisenburger DD
J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of DNA flow cytometry in non-Hodgkin's lymphoma.
Wu HM
J Tongji Med Univ; 1992; 12(2):65-70. PubMed ID: 1433420
[TBL] [Abstract][Full Text] [Related]
13. MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.
Oster W; Forsthuber T; Hennekeuser HH; Gamm H; Lindemann A; Schmitz G; Fuhr HG; Hinterberger R; Kreiter H; Thoenes W
Blut; 1990 Jan; 60(1):23-7. PubMed ID: 1688725
[TBL] [Abstract][Full Text] [Related]
14. Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.
Barista I; Tekuzman G; Firat D; Baltali E; Kansu E; Kars A; Ozisik Y; Ruacan S; Uzunalimoğlu B; Karaağaoğlu E
Jpn J Cancer Res; 1994 Dec; 85(12):1200-7. PubMed ID: 7531679
[TBL] [Abstract][Full Text] [Related]
15. AgNORs predictive value of prognosis in non-Hodgkin's lymphoma: comparison with flow cytometric cell cycle analysis.
Jakić-Razumović J; Uzarević B; Petrovecki M; Marusić M; Radman I; Labar B
Leuk Lymphoma; 1992 May; 7(1-2):165-70. PubMed ID: 1472929
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
Yahalom J; Varsos G; Fuks Z; Myers J; Clarkson BD; Straus DJ
Cancer; 1993 Apr; 71(7):2342-50. PubMed ID: 8453557
[TBL] [Abstract][Full Text] [Related]
17. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas.
Tondini C; Zanini M; Lombardi F; Bengala C; Rocca A; Giardini R; Buzzoni R; Valagussa P; Bonadonna G
J Clin Oncol; 1993 Apr; 11(4):720-5. PubMed ID: 8478665
[TBL] [Abstract][Full Text] [Related]
18. The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
Dreiher J; Shpilberg O; Raanani P; Chetrit A; Ben-Bassat I
Leuk Res; 1998 Nov; 22(11):997-1002. PubMed ID: 9783801
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of ploidy and proliferative activity evaluation by flow cytometry in poor prognosis non-Hodgkin's lymphomas.
De Lena M; Barletta A; Marzullo F; Lorusso V; Berardi F; Tommasi S; Mangia A; Paradiso A
Haematologica; 1992; 77(1):84-6. PubMed ID: 1398287
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of lymphocyte homing receptor and S phase fraction in non-Hodgkin's lymphoma.
Jalkanen S; Joensuu H; Klemi P
Blood; 1990 Apr; 75(7):1549-56. PubMed ID: 2180497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
